RecruitingPhase 4NCT06514547

Vaccine Immunity and Inflammation in the Aging Person Living With HIV


Sponsor

Hennepin Healthcare Research Institute

Enrollment

250 participants

Start Date

Jul 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age\>=18 years
  • HIV Diagnosis
  • On Antiretroviral Therapy with HIV Viral Load\<200 within last year
  • Age\>=18 years
  • HIV Ag-Ab test negative

Exclusion Criteria9

  • Other significant immunosuppressing condition
  • Age\< 18 years
  • Pregnancy (at enrollment)
  • Contraindication to pneumococcal vaccination
  • Known contraindication to non-clinical blood draws (severe anemia last hemoglobin \<8g/dl)
  • Subjects who, in the opinion of the Investigator, may be non-adherent to study schedules or procedures.
  • Adults unable to consent
  • Individuals with impaired ability to consent
  • Incarceration at time of enrollment

Interventions

BIOLOGICALConjugate Pneumococcal Vaccine 20 (PCV20)

Vaccine


Locations(1)

Hennepin Healthcare System

Minneapolis, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06514547


Related Trials